PEI-coated Fe₃O₄ magnetic nanoparticles for fast and segregative removal of uric acid from plasma

Y. Z. Pan^a, W. H. Wang^b, Y. Huang^c, C. X. Yi^d, X. Huang^{d,e*}

^a School of Chemical Engineering, Sichuan University of Science & Engineering, Zigong, Sichuan, 643000, P. R. China ^bSchool of Kinesiology, Shanghai University of Sport, Shanghai, 200438, P. R.

^{*}School of Kinesiology, Shanghai University of Sport, Shanghai, 200438, P. R. China

^cCollege of Lab Medicine, Hebei North University, Key Laboratory of Biomedical Materials of Zhangjiakou, Zhangjiakou, Hebei, 075000, P. R. China ^dSchool of Sports and Health Science, Tongren University, Tongren, Guizhou, 554300, P. R. China ^eScool of Physical Education, Guangxi University of Science and Technology, Liuzhou,

Scool of Physical Education, Guangxi University of Science and Technology, Liuzhou, Guangxi, 545006, P. R. China

Excess uric acid in blood would cause serious health consequences. Extracorporeal blood purification using solid phase adsorbents is considered as the most promising technique for uric acid removal for patients with nephropathy. In this work, PEI-coated Fe₃O₄ NPs have been synthesized to be a fast and segregative remover of uric acid. They present a fast and efficient adsorption behavior. Meanwhile, PEI-coated Fe₃O₄ NPs are magnetic separable and biocompatible. Therefore, PEI-coated Fe₃O₄ NPs hold a great potential in uric acid removal both in vitro and in vivo.

(Received September 8, 2021; Accepted January 29, 2022)

Keywords: Magnetic nanoparticles, PEI, Uric acid, Removal, Segregation

1. Introduction

Uric acid is the final product of purine nucleotide catabolism in human body. For healthy people, the production of uric acid is in a dynamic balance. While, when the concentration of uric acid in serum is over 416 µmol/L for men and 357 µmol/L for women, it is can be diagnosed as hyperuricemia^[1]. Usrate would crystallize resulting from the excess residual of uric acid in body and deposit to cause inflammation. This eventually leads to the formation of tophi and occurrence of gout ^[2]. Besides, diabetes, hypertension, nephrolith and angiocardiopathy are the most common complications with serious health consequences ^[3]. Reducing the high purine foods intake ^[4], administrating drugs to inhibit uric acid synthesis and synthase^[5], promote uric acid excretion and alkalify urine are effective way to treat hyperuricemia ^[6]. However, patients with nephropathy who suffer from renal failure or renal insufficiency are difficulty in uric acid excretion. They have to undergo hemodialysis to eliminate uric acid in clinic. Currently, extracorporeal blood purification using solid phase adsorbents is considered as the most promising technique. So far, some adsorbents such as mesoporous silica ^[7], polyethyleneimine (PEI)/SiO₂ particles ^[8], activated carbon microspheres ^[9, 10], polymer granules ^[11], and hydroxyapatite have been tested for their potential application to remove the excess uric acid ^[12]. Although their adsorption efficiencies are proved to be high, those adsorbents are weak in long adsorption time. In addition, all the studies have paid no attention to separate the adsorbents after uric acid adsorption. They are probably complicated in drawing out of the plasma. Therefore, a novel adsorbent which can realize fast and segregative removal of uric acid from plasma need to be developed.

^{*} Corresponding author: humphrey8531@hotmail.com https://doi.org/10.15251/DJNB.2022.171.137

Superparamagnetic iron oxide nanoparticles (Fe₃O₄ NPs) are of good magnetic guidance for biomedical applications both *in vitro* ^[13] and *in vivo* ^[14] by external magnetism. Fe₃O₄ NPs also have good performance on magnetic separation in biological nanomedicine ^[15]. It can be infer that uric acid adsorbents based on Fe₃O₄ NPs could be easily separated from plasma. On the other hand, biocompatible PEI has already been used for uric acid adsorption with high efficiency ^[8]. Herein, we have employed Fe₃O₄ NPs as the core and PEI as the surface to fabricate the novel uric acid adsorbents for fast and segregative removal. Their adsorption efficiency and hemocompatibility have been investigated in this work.

2. Materials and methods

2.1. Materials

 $FeCl_2 \cdot 4H_2O$ (Damao), hydrochloric acid (HCl), sodium hydroxide (NaOH), patassium nitrate (KNO₃) (Chuangdong), PEI (M_W= 25000, Adamas-beta®), uric acid assay kits, BCA protein quantitation kits (Nanjing Jianchen), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Dingguo), RPMI-1640 (Hyclone), fetal bovine serum (FBS), trypsin (Gibco)were commercially available and used as received. Human umbilical vein endothelial cells (HUVEC) were purchased from ScineCell.

2.2. Synthesis of PEI-coated Fe₃O₄ NPs

0.729 g of NaOH and 2.046 g of KNO₃ were dissolved in 150 mL of deionized water. Under N₂ protection, HCl solution containing 0.331 g of FeCl₂·4H₂O and 0.45 g of PEI was added dropwise under constant stirring. Then the mixture was held at 80 °C for 24 h, followed by an ice bath. The precipitation was collected by magnetic separation and washed three times with deionized water.

2.3. Characterization

The morphology of PEI-coated Fe_3O_4 NPs was observed by scanning electron microscopy (SEM, SU-70 HITACHI). The fourier transform infrared spectroscopy (FTIR) spectra were determined by fourier transform infrared spectrometer (Spectrum GX Perkin Elmer). The zeta potential was determined by by a dynamic light scattering instrument (Zetasizer Nano S90, Malvern). The magnetization value was determined by superconducting quantum interference device (MPMS-XL-7, Quantum Design).

2.4. Adsorption efficiency on uric acid of PEI-coated Fe₃O₄ NPs

Various mass of PEI-coated Fe₃O₄ NPs (W:W=1:0.5, 1:1, 1:5, 1:25, 1:50, PEI-coated Fe₃O₄ NPs:uric acid) were added into the high uric acid concentration plasma (above 420 μ mol/L). Those mixtures were placed in a four-dimensional rotating mixer for 0.5 h. After that, magnetic separation was use to collect the supernatant. The residual uric acid and protein in the supernatant was determined by uric acid assay kits and BCA protein quantitation kits, respectively. All the experiments repeated thrice.

2.5. Hemocompatibility of PEI- Fe₃O₄ NPs

The hemolysis rate and thromboresistant ratio of PEI-coated Fe_3O_4 NPs at 0.5 h with the above experimental concentrations were carried out to evaluated their hemocompatibility using the same processes as our previous work ^{[14].}

2.6. MTT proliferation assay

The HUVEC in their exponential growth phase were seeded into 96-well plates at a density of 5000 cells per well. After 12 h, PEI-coated Fe_3O_4 NPs suspension with above concentrations were added into the culture medium. 0.5 h later, PEI-coated Fe_3O_4 NPs were drawn out. MTT assay were used to determine the timely and 24 h's posterior cellular viability. All the experiments were repeated six times. The cells without any treatment were used as the positive control to set the cellular viability to 100%.

3. Results and discussion

PEI-coated Fe₃O₄ NPs were prepared based on the commonly used oxidative hydrolysis method. Their morphology was observed by SEM (Fig. 1a). PEI-coated Fe₃O₄ NPs were spherical and monodispersed. And their sizes were around 200 nm. The FTIR of PEI-coated Fe₃O₄ NPs was shown in Fig. 1b. The adsorption peak around 586 cm⁻¹ resulted from Fe-O vibrations. And there were two intense bands at 1630 and 3430 cm⁻¹, assigned to bending vibrations and stretching vibrations of N-H bond, respectively. These results indicated that PEI was successfully coated on the Fe₃O₄ NPs. Meanwhile, the zeta potential of PEI-coated Fe₃O₄ NPs had increased to 48.5±9.2 mV due to the PEI coating. Primally negative Fe₃O₄ NPs^[16] were surface-functionalized with abundant amino. So PEI-coated Fe₃O₄ NPs became positive and stable. Fig. 1d showed the magnetization curve of PEI-coated Fe₃O₄ NPs were superparamagnetic because there was no hysteresis and their remanence as well as coercivity were zero. And they could be easily gathered by external magnetism.

Superparamagnetism was essential for materials to realize facile magnetic separation ^[17-19]. It was well known that the shape and size of the nanoparticles greatly influenced their magnetic performance. Generally, the bigger size of magnetic core and the thinner coating of modified shell resulted in higher saturation magnetization^[20]. Therefore, the size of magnetic adsorbents from plasma were bigger than 100 nm to improve enough magnetic attraction ^[21-23]. The saturation of PEI-coated Fe₃O₄ NPs of which size were around 200 nm got as high as 52.61 emu/g. This was close to that of those magnetic adsorbents used in substances removal from plasma ^[19] ^[23, 24]. In view of this, it was believable that PEI-coated Fe₃O₄ NPs were able to easily be separate from plasma by magnetic separation.



Fig. 1. Characterization. a SEM image; b FTIR; c Zeta potential; d Magnetic hysteresis loop.

Next, the adsorption efficiency on uric acid by PEI-coated Fe_3O_4 NPs had been investigated. Fig. 2 showed the adsorption ratio. With the mass of PEI-coated Fe_3O_4 NPs increased, more uric acid had been adsorbed. The uric acid adsorption behavior was in a concentration-dependent manner. When the ratio reached 1:1, more than 44% of uric acid had been adsorbed.

The adsorption quantity of uric acid on PEI-coated Fe_3O_4 NPs was much larger than other adsorbents ^[8, 9, 11]. Although the removal ratio of PEI-coated Fe_3O_4 NPs was lower than that of spherical carbonaceous adsorbent of which ratio approached 80%, the removal time of PEI-coated Fe_3O_4 NPs was much shorter than that of spherical carbonaceous adsorbent of which time was 24 h ^[10]. This result indicated that PEI-coated Fe_3O_4 NPs could become the fast and efficient uric acid adsorbents.



Fig. 2. The adsorption effect of uric acid by PEI-coated Fe_3O_4 NPs.

After adsorption, the zeta potential of PEI-coated Fe_3O_4 NPs decreased to -20 ± 3.6 mV (Fig. 3a). And, there no new intense band appeared in the FTIR except the spectra of PEI-coated Fe_3O_4 NPs and uric acid (Fig. 3b). Positive PEI-coated Fe_3O_4 NPs produced electrostatic interaction for negative uric acid. Therefore, the fast and efficient adsorption mainly depended on the electrostatic interaction.



Fig. 3. The zeta potential (a) and FTIR (b) of PEI-coated Fe_3O_4 NPs after uric acid adsorption.

In addition, BCA text was used to evaluate whether PEI-coated Fe_3O_4 NPs adsorbed protein during the uric acid adsorption. Similarly, the adsorption behavior was also in a concentration-dependent manner. However, When the ratio was 1:1 ($C_{PEI-coated Fe3O4 NPs}=70 \mu g/mL$), less than 10% protein had been adsorbed, of which amount was far below the adsorption amount of uric acid. The probable reason might be that uric acid with small molecular rapidly adhered to the surface of PEI-coated Fe₃O₄ NPs, leaving little space to protein.



Fig. 4. The protein adsorption by PEI-coated Fe_3O_4NPs .

Since, PEI-coated Fe_3O_4 NPs were expected to be used as a magnetic guided uric acid remover in blood vessels, their hemocompatibility and cytotoxicity to HUVEC were evaluated. Tab. 1 and Tab. 2 listed the hemolysis rates and thromboresistant ratios of PEI-coated Fe_3O_4 NPs respectively. All the hemolysis rate were lower than 5%. It showed that PEI-coated Fe_3O_4 NPs didn't cause hemolysis with those concentrations. Besides, PEI-coated Fe_3O_4 NPs represented certain anticoagulant effect mainly because some clotting proteins had been adsorbed.

Concentration (µg/mL)	Hemolysis rate (%)
1.40	0.13±0.05
2.80	0.21±0.07
14	0.78±0.09
70	1.28±0.14
140	1.63±0.12

Table 1. Hemolysis rates of PEI-coated Fe₃O₄ NPs.

Table 2. Thromboresistant ratios of PEI-coated Fe_3O_4 NPs.

Concentration (µg/mL)	Thromboresistant ratio (%)
1.40	35.16±1.32
2.80	37.79±1.95
14	48.61±1.17
70	58.17±2.47
140	60.34±2.93

In addition, MTT test was performed to test the growth inhibition of various concentrations of PEI-coated Fe₃O₄ NPs to HUVEC. The cellular viability at the end of adsorption was slightly lower than that of 24 h later. Except for the experimental group with the highest concentration, the viability of HUVEC in other experimental groups were all above 75% (Fig. 5). And those concentrations were deemed to be nearly no cytotoxicity ^[25]. Accordingly, PEI-coated Fe₃O₄ NPs were not only hemocompatible but also cytocompatible under certain concentrations. Therefore, they could be a safe uric acid remover *in vivo*.



Fig. 5. Cytotoxicity of PEI-coated Fe₃O₄NPs.

4. Conclusion

In conclusion, PEI-coated Fe_3O_4 NPs have been used to adsorb excessive uric acid in plasma. They present a fast and efficient adsorption behavior. More importantly, PEI-coated Fe_3O_4 NPs are superparamagnetic which can easily be separate from plasma by magnetic separation. In view of their good hemocompatibility and cytocompatibility, PEI-coated Fe_3O_4 NPs hold a great potential in uric acid removal both *in vitro* and *in vivo*.

Acknowledgements

This work was funded by National Natural Science Foundation of China (81860324 & 31800839), Talent introduction project of Sichuan Institute of Technology (E10402600), Highlevel Innovative Talents in Guizhou Province (2018-2016-023).

References

[1] N. S. Chaudhary, S. L. Bridges, K. G. Saag et al. Hypertension 75(1), 246 (2019); https://doi.org/10.1161/HYPERTENSIONAHA.119.13580

[2] N. Dalbeth, H. K. Choi, L. A. B. Joosten et al., Nature Reviews Disease Primers 5(1), 1 (2019); https://doi.org/10.1038/s41572-019-0115-y

[3] V. V. Fomin, T. E. Morosova, V. V. Tsurko. Terapevticheskii Arkhiv 91(12), 75 (2019); https://doi.org/10.26442/00403660.2019.12.000173

[4] R. Li, Y. Kang, C. Li. Asia Pacific Journal of Clinical Nutrition 27, 1344 (2018).

[5] S. Higa, D. Shima, N. Tomitani et al., Journal of Clinical Hypertension 21(9), 1713 (2019); https://doi.org/10.1111/jch.13707

[6] R. Bao, M. Liu, D. Wang et al., Frontiers in Pharmacology 10, 1(2019); https://doi.org/10.3389/fphar.2019.01464

[7] L. X. Zhang, M. Zhu, L. M. Guo et al., Nano-Micro Letters 1(001), 14 (2009); https://doi.org/10.1007/BF03353599

[8] B. Gao, P. Jiang, H. Lei. Materials Letters 60(28), 3398 (2006); https://doi.org/10.1016/j.matlet.2006.03.086

[9] X. Sun, Y. Tang, D. Di et al., New Journal of Chemistry 39(7), 5513 (2015); https://doi.org/10.1039/C4NJ01777C

[10] M. T. Sultan, B. M. Moon, J. W. Yang et al., Materials Science & Engineering C 97, 55 (2019); <u>https://doi.org/10.1016/j.msec.2018.12.021</u>

[11] A. P. Leshchinskaya, N. M. Ezhova, O. A. Pisarev, Reactive and Functional Polymers 102, 101 (2016); <u>https://doi.org/10.1016/j.reactfunctpolym.2016.02.014</u>

[12] C. Zhang, Z. Xiao, T. Qin et al., Journal of Saudi Chemical Society 23(2), 249 (2019); https://doi.org/10.1016/j.jscs.2018.11.009

[13] Z. Yu, Y. Guo, H. Dai et al., Materials Express 9(5), 467 (2019); https://doi.org/10.1166/mex.2019.1525

[14] X. Huang, J. Lu, Y. Danyang et al., Nanotechnology 26(12), 1 (2015); https://doi.org/10.1088/0957-4484/26/12/125101

[15] Y. Ma, T. Chen, M. Z. Iqbal et al., Electrophoresis 40(16-17), 2011 (2019); https://doi.org/10.1002/elps.201800401

[16] P. Hernández, A. Lucero-Acuña, I. E. Moreno-Cortez et al., Journal of Nanoscience and Nanotechnology 20(4), 2063 (2020); <u>https://doi.org/10.1166/jnn.2020.17324</u>

[17] S. Gauri, K. B. Gan, S.-M. Then, Microsystem Technologies 25(04), 1379 (2019); https://doi.org/10.1007/s00542-018-4102-0

[18] H. M. Kim, D. M. Kim, C. Jeong et al., Scientific Reports 8, 1 (2018); https://doi.org/10.1038/s41598-018-29948-9

[19] K. Du, X. Liu, S. Li et al., ACS Sustainable Chemistry & Engineering 6(9), 11578 (2018); https://doi.org/10.1021/acssuschemeng.8b01699

[20] L. Kopanja, M. Tadić, S. Kralj et al., Ceramics International 44(11), 12340 (2018); https://doi.org/10.1016/j.ceramint.2018.04.021

[21] L. Su, Y. Jin, Y. Huang et al., Journal of Separation Science 40(10), 2269 (2017); https://doi.org/10.1002/jssc.201700080

[22] D. Jiang, T. Hu, H. Zheng et al., Chemistry - An European Journal 24(41), 10390 (2018); https://doi.org/10.1002/chem.201800092

[23] Y. Zhang, M. Zhang, J. Yang et al., Journal of Alloys & Compounds 695, 3256 (2017); https://doi.org/10.1016/j.jallcom.2016.11.239

[24] D. Jiang, X. Li, X. Lv et al., Talanta 185, 461(2018); https://doi.org/10.1016/j.talanta.2018.04.006

[25] G. Ciapetti, E. Cenni, L. Pratelli et al., Biomaterials 14(5), 359 (1993); https://doi.org/10.1016/0142-9612(93)90055-7